NEU 1.54% $19.86 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1082

  1. 882 Posts.
    lightbulb Created with Sketch. 390
    agreed mate, the fact is an acquirer will always try to pay as little as possible to realise any synergies and value in the purchase.

    why would someone pay $100M for something if they only expect it to generate an NPV of $100M? It’s a completely fruitless exercise and waste of time and money.

    even if all the phase 2s of 2591 are positive, I don’t see any big pharma coughing up billions upon billions to acquire NEU. The market cap is around $2.5bn now, say for arguments sake it gets to $3.5bn with all the phase 2s in the bag, you might only get a 50-70% premium on that.


 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.